New China R&D hub takes its place in Merck Serono's global network
This article was originally published in Scrip
Merck Serono has inaugurated a new R&D hub facility in China, its fourth worldwide, which will focus on biomarker characterisation, pharmacogenomics and other bioanalytical research relevant to the country's healthcare needs.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.